Browse > Article
http://dx.doi.org/10.5012/bkcs.2010.31.8.2163

Bayesian Model for the Classification of GPCR Agonists and Antagonists  

Choi, In-Hee (Institute of Life Science & Biotechnology, Yonsei University)
Kim, Han-Jo (Bioinformatics & Molecular Design Research Center)
Jung, Ji-Hoon (Department of Life Science & Biotechnology, Yonsei University)
Nam, Ky-Youb (Bioinformatics & Molecular Design Research Center)
Yoo, Sung-Eun (Korea Research Institute of Chemical Technology)
Kang, Nam-Sook (Korea Research Institute of Chemical Technology)
No, Kyoung-Tai (Institute of Life Science & Biotechnology, Yonsei University)
Publication Information
Abstract
G-protein coupled receptors (GPCRs) are involved in a wide variety of physiological processes and are known to be targets for nearly 50% of drugs. The various functions of GPCRs are affected by their cognate ligands which are mainly classified as agonists and antagonists. The purpose of this study is to develop a Bayesian classification model, that can predict a compound as either human GPCR agonist or antagonist. Total 6627 compounds experimentally determined as either GPCR agonists or antagonists covering all the classes of GPCRs were gathered to comprise the dataset. This model distinguishes GPCR agonists from GPCR antagonists by using chemical fingerprint, FCFP_6. The model revealed distinctive structural characteristics between agonistic and antagonistic compounds: in general, 1) GPCR agonists were flexible and had aliphatic amines, and 2) GPCR antagonists had planar groups and aromatic amines. This model showed very good discriminative ability in general, with pretty good discriminant statistics for the training set (accuracy: 90.1%) and a good predictive ability for the test set (accuracy: 89.2%). Also, receiver operating characteristic (ROC) plot showed the area under the curve (AUC) to be 0.957, and Matthew's Correlation Coefficient (MCC) value was 0.803. The quality of our model suggests that it could aid to classify the compounds as either GPCR agonists or antagonists, especially in the early stages of the drug discovery process.
Keywords
Bayesian; Classification; GPCR; Agonists; Antagonists;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Science Integrity${\circledR}$. http://integrity.prous.com ${\copyright}$ Prous Science, a Thomson Scientific business, Stamford, CT, USA, 2007.
2 PreADMET 2.0, BMDRC, Seoul, Korea, 2008.
3 $Spotfire^{\circledR}\;DecisionSite^{\circledR}$ 9.1.1. http://spotfire.tibco.com, Somerville, MA, USA, 2008.
4 Sciabola, S.; Carosati, E.; Cucurull-Sanchez, L.; Baroni, M.; Mannhold, R. Bioorg. Med. Chem. 2007, 15, 6450.   DOI
5 Rogers, D.; Brown, R. D.; Hahn, M. J. Biomol. Screen. 2005, 10, 682.   DOI
6 Matthews, B. W. Biochim. Biophys. Acta 1975, 405, 442.   DOI
7 Baldi, P.; Brunak, S.; Chauvin, Y.; Andersen, C. A.; Nielsen, H. Bioinformatics 2000, 16, 412.   DOI
8 Lescot, E.; Bureau, R.; Rault, S. Peptides 2008, 29, 680.   DOI
9 Lescot, E.; Sopkova-de Oliveira Santos, J.; Dubessy, C.; Oulyadi, H.; Lesnard, A.; Vaudry, H.; Bureau, R.; Rault, S. J. Chem. Inf. Model. 2007, 47, 602.   DOI
10 Radestock, S.; Weil, T.; Renner, S. J. Chem. Inf. Model. 2008, 48, 1104.   DOI
11 Brink, C. B.; Harvey, B. H.; Bodenstein, J.; Venter, D. P.; Oliver, D. W. Br. J. Clin. Pharmacol. 2004, 57, 373.   DOI
12 Ellis, C. Nat. Rev. Drug Discov. 2004, 3, 577.   DOI
13 Chen, B.; Harrison, R. F.; Papadatos, G.; Willett, P.; Wood, D. J.; Lewell, X. Q.; Greenidge, P.; Stiefl, N. J. Comput. Aided Mol. Des. 2007, 21, 53.   DOI
14 Manallack, D. T.; Pitt, W. R.; Gancia, E.; Montana, J. G.; Livinstone, D. J.; Ford, M. G.; Whitley, D. C. J. Chem. Inf. Comp. Sci. 2002, 42, 1256.   DOI
15 von Korff, M.; Steger, M. J. Chem. Inf. Comp. Sci. 2004, 44, 1137.   DOI
16 Xia, X.; Maliski, E. G.; Gallant, P.; Rogers, D. J. Med. Chem. 2004, 47, 4463.   DOI
17 Balakin, K. V.; Lang, S. A.; Skorenko, A. V.; Tkachenko, S. E.; Ivashchenko, A. A.; Savchuk, N. P. J. Chem. Inf. Comp. Sci. 2003, 43, 1553.   DOI
18 Vogt, I.; Ahmed, H.; Auer, J.; Bajorath, J. Mol. Divers. 2008,12, 25.   DOI
19 Selzer, P.; Ertl, P. QSAR Comb. Sci. 2005, 24, 270.   DOI
20 Hassan, M.; Brown, R. D.; Varma-O’Brien, S.; Rogers, D. Mol. Divers. 2006, 10, 283.   DOI
21 Prathipati, P.; Ma, N. L.; Keller, T. H. J. Chem. Inf. Model. 2008, 48, 2362.   DOI
22 Ertl, P.; Roggo, S.; Schuffenhauer, A. J. Chem. Inf. Model. 2008, 48, 68.   DOI
23 Scitegic Inc., 9665 Chesapeake Dr., Suite 401, San Diego, CA 92123, USA, PipeLine Pilot 7.0.1, 2008, version 7.0.1.
24 Okuno, Y.; Tamon, A.; Yabuuchi, H.; Niijima, S.; Minowa, Y.; Tonomura, K.; Kunimoto, R.; Feng, C. Nucl. Acids Res. 2008, 36, D907.   DOI
25 Bleicher, K. H.; Green, L. G.; Martin, R. E.; Rogers-Evans, M. Curr. Opin. Chem. Biol. 2004, 8, 287.   DOI
26 Fredriksson, R.; Lagerstrom, M. C.; Lundin, L.-G.; Schioth, H. B. Mol. Pharmacol. 2003, 63, 1256.   DOI
27 Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. Science 2007, 318, 1258.   DOI